Research digest
melanotan: a cyclic alpha-MSH analog studied across four research domains from 1989 to 2026
26 primary findings indexed. Phase I human data available for pigmentation and erectile function. Serious adverse events documented in case reports. One approved analog (afamelanotide). Zero approved indications for MT-II.
What Is Melanotan?
melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH): Melanotan I (afamelanotide) and Melanotan II.
Origin and development history
U of Arizona, 1989
melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH): Melanotan I (afamelanotide, a linear 13-amino-acid analog) and Melanotan II (a cyclic 7-amino-acid analog). Both were developed at the University of Arizona by Hruby and Hadley beginning in the late 1980s as truncated, cyclized, enzymatically resistant derivatives of the endogenous alpha-MSH tridecapeptide.[1]
The original research rationale was photoprotection: if a synthetic alpha-MSH analog could drive melanin production in human skin, it might reduce UV-induced DNA damage and lower skin cancer incidence.[1] That rationale produced three decades of published research, two approved compounds (afamelanotide for erythropoietic protoporphyria; bremelanotide/PT-141 for hypoactive sexual desire disorder), and a persistent unapproved compound — Melanotan II — still studied but approved nowhere.[2]
Receptor binding and melanogenesis cascade
MC1R / MC4R primary
Melanotan II binds non-selectively to melanocortin receptors 1, 3, 4, and 5 (MC1R–MC5R). MC1R activation drives melanogenesis — the cAMP/PKA/CREB/MITF cascade that upregulates tyrosinase and shifts melanin synthesis toward the darker eumelanin form.[4] MC4R activation in the central nervous system mediates appetite suppression, the erectogenic effect, and the autonomic side effects (nausea, yawning) observed in early human trials.[5][6][7]
This site is a drill-down index of that literature. Every quantitative finding is cited. Every adverse event is documented. The melanotan research literature begins with the melanogenesis mechanism; the melanotan dosage research section documents what Phase I trials actually studied; the melanotan side effects record covers the case reports of renal infarction, rhabdomyolysis, dysplastic nevi, and mucosal melanoma. The full reference list is at /references.
Melanotan II vs. Melanotan I: How the Two Analogs Differ
MT-I is linear and MC1R-selective. MT-II is cyclic and binds MC1R, MC3R, MC4R, and MC5R — a broader footprint that explains both its wider pharmacology and its more complex adverse-event profile.
Structural differences and receptor selectivity
1024.2 Da / cyclic
Melanotan I (afamelanotide) is a linear 13-amino-acid analog with preferential MC1R selectivity. Melanotan II is a cyclic 7-amino-acid heptapeptide (Cyclo(His-Phe-Arg-Trp-Gly), MW 1024.2 Da) with broader MC1R/MC3R/MC4R/MC5R activity. The cyclization of MT-II improved its metabolic stability and receptor potency relative to MT-I — and expanded its biological footprint beyond pigmentation into appetite suppression, sexual behavior, and neuroprotection.[2]
Regulatory divergence: approved vs. unapproved
MT-I approved / MT-II none
The practical divergence: MT-I's MC1R selectivity made it a clean photoprotection candidate with a manageable adverse-event profile. EU approval (Scenesse, 2014) and FDA approval (2019) followed for erythropoietic protoporphyria.[15] MT-II's broader receptor activity produced measurable erectogenic and anorexigenic effects — findings that proved commercially valuable when Palatin Technologies isolated MT-II's MC4R-active descendant bremelanotide (PT-141), which received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women.[19] MT-II itself has no approved indication in any jurisdiction.
The Melanotan II vs. PT-141 distinction matters for interpreting the literature: not all findings for afamelanotide transfer to MT-II, and not all MT-II adverse events have been observed with MT-I.
What Is Melanotan Made Of?
Melanotan II is a fully synthetic peptide produced by solid-phase peptide synthesis. The cyclic structure provides substantially better enzymatic stability than the linear alpha-MSH precursor.
Molecular structure and bioavailability
4.6% oral BA (rat)
Melanotan II is a fully synthetic peptide — not derived from biological sources. It is produced by solid-phase peptide synthesis from standard amino acid precursors. The compound consists of seven amino acids in a cyclic arrangement: Cyclo(His-Phe-Arg-Trp-Gly), with an amide bond forming the cyclic bridge. Molecular weight: 1024.2 Da.[1]
Lyophilized (freeze-dried) MT-II powder is the standard research form. Oral bioavailability in rats is 4.6% — low enough that subcutaneous injection is the standard research and clinical route.[1] The cyclic structure provides substantially better enzymatic stability than the linear alpha-MSH precursor, which is why MT-II remains bioactive at doses far lower than native alpha-MSH.
Research Applications of Melanotan II
Published research has investigated Melanotan II across four distinct domains: pigmentation, erectile dysfunction, appetite suppression, and neuroprotection.
Pigmentation and melanogenesis
Phase I n=3
Erectile dysfunction — Phase I trials
8/10 responders (1998)
Appetite suppression — rodent models
80% adiposity reduction (rat)
Neuroprotection — peripheral nerve regeneration
20 µg/kg bell-shaped response
A rat study found that MT-II at 20 µg/kg subcutaneous promoted peripheral nerve regeneration after sciatic crush injury and partially protected against cisplatin-induced toxic neuropathy — with a bell-shaped dose-response indicating the middle dose was effective while lower and higher doses were not.[21]
Melanotan II Research in Male Subjects
Three human trials enrolled male subjects. The 1996 pilot and two Wessells trials (1998, 2000) constitute the entirety of controlled human dose data for MT-II.
1996 Phase I pilot — Dorr et al.
n=3 / pigment in 2 of 3
In the 1996 pilot Phase I study, 3 healthy males received 5 low-dose injections (0.01–0.03 mg/kg/day); measurable pigmentation increases appeared in 2 of 3, and spontaneous penile erections lasting 1–5 hours post-injection were an incidental finding.[3]
1998 double-blind crossover — Wessells et al.
38 min rigidity vs 3 min (p=0.0045)
A 1998 double-blind crossover trial in 10 men with psychogenic ED found 0.025 mg/kg produced erections in 8 of 10 subjects; mean tip rigidity >80% lasted 38 minutes vs. 3 minutes for placebo (p=0.0045).[5]
2000 organic ED trials — Wessells et al.
17/20 responders; 45 min duration
A 2000 trial in 20 men with organic ED: 17 of 20 subjects had erections; increased sexual desire followed 68% of active doses vs. 19% of placebo.[6] A second 2000 trial in 10 men with organic ED confirmed erection duration approximately 45 minutes with active drug vs. 1.9 minutes for placebo.[7]
The erections produced by MT-II in these trials occurred without visual sexual stimulation — a finding that localizes the mechanism to central MC4R signaling rather than peripheral vascular effects.